Published in PLoS One on July 22, 2011
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol (2010) 9.72
Regulatory T cells in transplantation tolerance. Nat Rev Immunol (2003) 6.42
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90
Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med (2005) 5.02
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001) 3.99
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 3.92
IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol (2007) 3.82
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol (2004) 3.59
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2007) 2.10
CD4+ T cell regulation of CD25 expression controls development of short-lived effector CD8+ T cells in primary and secondary responses. Proc Natl Acad Sci U S A (2009) 2.01
A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol (2007) 1.91
Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant (2007) 1.67
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res (2006) 1.58
Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol (2002) 1.55
Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant (2003) 1.48
Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol (2003) 1.35
CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J Exp Med (2003) 1.27
Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS One (2008) 1.16
Location and time-dependent control of rejection by regulatory T cells culminates in a failure to generate memory T cells. J Immunol (2008) 1.09
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol (1999) 1.04
Regulatory T cells in viral hepatitis. World J Gastroenterol (2007) 0.99
Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol (2010) 0.92
Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol (2010) 0.91
T regulatory cells and transplantation tolerance. Transplant Rev (Orlando) (2010) 0.90
Analysis of the peripheral T-cell repertoire in kidney transplant patients. Eur J Immunol (2010) 0.89
Perforin, Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft rejection: analyses on serial biopsies suggest methodological issues. Transplantation (2006) 0.89
Regulatory T cells can prevent memory CD8+ T-cell-mediated rejection following polymorphonuclear cell depletion. Eur J Immunol (2010) 0.84
A novel micro-cell-mediated lympholytic assay for the evaluation of regulatory cells in human alloreactive CTL responses. J Immunol Methods (2003) 0.79
T cell tolerance in transplantation: possibilities for therapeutic intervention. Expert Opin Ther Targets (2002) 0.78
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med (2005) 4.27
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol (2012) 3.11
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol (2003) 2.88
Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med (2007) 2.86
Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl (2007) 2.31
National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl (2013) 2.00
Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog Horm Res (2002) 1.93
Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant (2003) 1.64
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol (2011) 1.56
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol (2006) 1.50
Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol (2009) 1.50
Heterogeneity of cognitive trajectories in diverse older persons. Psychol Aging (2010) 1.44
Regulation of alloimmune responses (GvH reactions) in vitro by autologous donor bone marrow cell preparation used in clinical organ transplantation. Transplantation (2002) 1.42
National survey of adult transplant hepatologists on the pediatric-to-adult care transition after liver transplantation. Liver Transpl (2015) 1.41
Impairing oral tolerance promotes allergy and anaphylaxis: a new murine food allergy model. J Allergy Clin Immunol (2008) 1.36
A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation (2002) 1.32
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Am J Transplant (2005) 1.29
Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 1.28
Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol (2007) 1.26
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation (2005) 1.25
Operative risk of total hip and knee arthroplasty in cirrhotic patients. J Arthroplasty (2005) 1.15
Proposed classification of complications after live donor nephrectomy. Urology (2006) 1.15
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation (2007) 1.13
Allosensitization of islet allograft recipients. Transplantation (2007) 1.13
Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation (2002) 1.11
Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation (2007) 1.08
Relation of plasma homocysteine to plasma amyloid beta levels. Neurochem Res (2006) 1.06
The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06
Pretransplant evaluation of renal transplant candidates. Semin Nephrol (2002) 1.03
Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation (2006) 1.02
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant (2005) 1.01
Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun (2012) 1.01
Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation (2005) 1.00
Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions. Biomaterials (2011) 1.00
Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation. J Immunol (2010) 1.00
The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 0.99
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 0.99
Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis. J Immunol (2008) 0.98
Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans. Transplantation (2013) 0.98
Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients. Transplantation (2011) 0.97
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation (2004) 0.96
Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation (2015) 0.96
The DQ barrier: improving organ allocation equity using HLA-DQ information. Transplantation (2013) 0.95
Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol (2003) 0.95
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation (2004) 0.94
The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation (2010) 0.93
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation (2003) 0.93
Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation (2011) 0.93
A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum (2005) 0.93
TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol (2010) 0.92
Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol (2004) 0.92
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. Transplantation (2008) 0.92
Use of older controlled non-heart-beating donors for liver transplantation. Transplantation (2003) 0.92
Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation. Exp Cell Res (2008) 0.92
Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine (2004) 0.91
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant (2008) 0.91
Prevention of allograft rejection by amplification of Foxp3(+)CD4(+)CD25(+) regulatory T cells. Transl Res (2008) 0.91
Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol (2009) 0.91
Immune "tolerance profiles" in donor bone marrow infused kidney transplant patients using multiple ex vivo functional assays. Hum Immunol (2010) 0.91
Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transpl (2015) 0.90
Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. J Immunol (2012) 0.90
Sequential kidney/islet transplantation using prednisone-free immunosuppression. Am J Transplant (2002) 0.89
Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol (2011) 0.89
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation (2015) 0.88
Donor bone marrow infusion in deceased and living donor renal transplantation. Yonsei Med J (2004) 0.88
FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation (2007) 0.88
Laparoscopic living donor nephrectomy: a single-center sequential experience comparing hand-assisted versus standard technique. Urology (2007) 0.88
Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation (2010) 0.88
Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation (2002) 0.88
Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow. Hum Immunol (2004) 0.87
HLA-DQ barrier: effects on cPRA calculations. Transplantation (2013) 0.87